



Cancer
Research Society

**ACCELERATING DISCOVERIES,
ACCELERATING IMPACT.**

**2024-2025
IMPACT
REPORT**





“For 80 years, we have carried forward the vision of our founders with the same conviction: by accelerating discoveries through research, we strengthen our impact to outsmart cancer—today and for generations to come.”

Manon Pepin

President and Chief Executive Officer

SUMMARY

This Impact Report presents the activities and financial information of the Cancer Research Society (CRS) from September 1st, 2024, to August 31st, 2025.

Message from the President and CEO, and the Chairman of the Board of Directors	4
100% Research for Over 80 Years	6
Team	8
Board of Directors	8
Scientific Advisory Committee	9
Management Team	10
State of Cancer in Canada	11
Research	13
Our Impact	13
Funding Across the Research Spectrum	14
Evaluation Committees	15
Annual Programs	16
Targeted Programs	17
Clinical Trials	18
Promising Research Projects	19
Cancer Research Funding	21
Signature Events	22
Challenge Against Cancer Program	24
Financial Information	26
Transforming the Future, One Discovery at a Time	28

MESSAGE FROM THE PRESIDENT AND CEO, AND THE CHAIRMAN OF THE BOARD OF DIRECTORS

80 Years of Commitment and Impact

This year stands out for large achievements that have helped advance cancer research in concrete ways. We also celebrated the organization's 80th anniversary.

For eight decades, the Cancer Research Society (CRS) has supported some of the most promising research projects, the careers of innovative scientists, and, in doing so, supported people affected by cancer and their families across the country.

This anniversary marks more than a historic milestone: it reflects the importance of the CRS in Canada's research ecosystem and our commitment to continuing this vital work for years to come.

Updating the Strategic Plan

Over the past year, we updated our 2022–2027 strategic plan and revisited our initiatives for the 2026–2028 period.

Our ambition remains to build on the historic successes of the past five years by focusing on three strategic pillars that guide all our actions:

- **Increasing the visibility** of CRS, to raise awareness of our mission and rally more partners and donors;

- **Growing the funds** dedicated to cancer research and to give scientists the means to achieve major breakthroughs;
- **Maximizing the impact** of allocated funds, by investing in high-potential transformative projects to better prevent, detect, and treat cancer.

By continuing on this path, we aim for a future where research will pave the way for tangible and lasting scientific breakthroughs, while strengthening our leadership role within Canada's cancer research ecosystem.

[Learn more](#)

A Strong Mission and a Clear Identity

In this context, it was essential to better define what sets our organization apart; why donors and partners choose us. This reflection is summed up in a simple and powerful statement:

“Accelerating discoveries, accelerating impact.”

Through its expertise, the Cancer Research Society accelerates the impact of cancer research by identifying and funding the most promising projects in Canada.

Our approach is driven by several key levers:

- The diversity of our programs, tailored to researchers at every stage of their career;
- Sustained growth in our investments over the past five years;
- Strategic partnerships that amplify our reach;
- An unwavering commitment to scientific excellence, supported by our evaluation committees and Scientific Advisory Committee.

Together, these strengths allow us to support the most promising research and maximize its impact so that every scientific advancement directly benefits people affected by cancer and helps save lives.

A Historic Investment

This year, we are especially proud to have reached a historic milestone: supporting a record 316 research projects, with a total commitment of \$17 million. This unprecedented support will give researchers and their teams the means to carry out innovative projects that address all types of cancer.

Essential Support

It is essential, in this annual reflection, to express our sincere gratitude to our donors and partners. Our success relies entirely on your commitment and trust, which inspires and fuels our motivation every day. Thanks to you, we move forward together, guided by hope and shared determination to make a real difference for people affected by the disease through research.

We would also like to express our heartfelt thanks to the members of the Board of Directors, the Scientific Advisory Committee, and all members of the evaluation committees. Your involvement, dedication, and expertise are at the heart of our organization and enable us to continually raise the bar for excellence.

Finally, a sincere thank you to all CRS employees, who work every day to make a difference and outsmart cancer.



Manon Pepin
President and Chief
Executive Officer



Christian M. Paupe
Chairman of the
Board of Directors

100% RESEARCH FOR OVER 80 YEARS

Accelerating Discoveries

In 1945, after facing her mother's cancer diagnosis, Betty Caplan felt compelled to make a real difference in cancer research.

When she realized that no organization was supporting research in Canada, she decided to create the Cancer Research Society (CRS) with the help of her friends Etta Kastner, Hattie Rolbin and Mildred Singer.

Since its founding 80 years ago, the mission of CRS has remained unchanged: to exclusively fund research on all types of cancer to prevent, detect, and treat the disease.

Watch the video of Julia Gersovitz, Betty Caplan's niece, as she highlights the strength of the CRS' mission.

6

Accelerating Impact

Our funding programs support innovative research projects aimed at improving the prevention, detection, and treatment of all types of cancer.

In addition to Operating Grants, Doctoral Research Awards and funding for the Next Generation of Scientists, several targeted and partnership programs have been developed over time.

[View our funding programs](#)

Beyond our grant programs, the past eight decades has allowed CRS to launch various initiatives to ensure the ongoing impact of its mission, including annual campaigns, signature events, the Challenge Against Cancer program, and more.

Together, Let's Continue Outsmarting Cancer

Every dollar makes a difference in funding cancer research and improving the lives of those affected by the disease. CRS is a recognized leader in funding cancer research in Canada. In this spirit, we have funded all of the country's cancer research centers over the years.

Visit the [Our History](#) page to learn more about the CRS's 80-year journey, and to help us write the next chapter of our story.



TEAM

BOARD OF DIRECTORS

The CRS team can count on the support of a dedicated and engaged Board of Directors involved in the organization's many activities. These experts, from across Canada, enrich our decision-making and help ensure the success of our initiatives.

Following his mandate as President of our Scientific Advisory Committee from 2020 to 2024, we welcomed Dr. Mark Basik as a new board member.

We would like to thank Peter McCarthy for his contribution as a board member from 2019 to 2024.

Thank you to all members of the Board of Directors for their volunteer contributions in support of advancing cancer research and for their contribution to the various committees.



**Chairman
of the Board**

Christian M. Paupe
Corporate Director



**Vice-president
and Secretary**

Heidi Lange, CRHA
Partner, Richter



Treasurer

Marie Valcourt, CPA
Partner, KPMG LLP

Board Members



**Dr. Mark
Basik, MD**

Herbert Black Professor
of Surgical Oncology,
McGill University
Surgical Oncologist, Lady
Davis Institute, Jewish
General Hospital (JGH)
Head of the Cancer
Genomics and
Translational Research
laboratory



**Peter
Clair**

Director and Market
Lead, National
Accounts, Québec,
Scotiabank



**Ghassan
Deko**

Vice President
Commercial Financial
Services
RBC Royal Bank



**Benoît
Durocher**

Executive
Vice-President
and Chief Economic
Strategist
Addenda Capital Inc.



**Dr. Alexandra T.
Greenhill, MD**

Founder, CEO and
Chief Medical Officer
Careteam
Technologies



**Carson
Loh**

Regional
Vice President,
Richmond Market
RBC Royal Bank
(British Columbia)



**Annie
Marsolais**

Chief Marketing
Officer



**François
Painchaud**

Lawyer and Partner
ROBIC



**Sean
O'Brien**

Executive
Vice-President,
Operational Efficiency
iA Financial Group



**Dr. George
Zogopoulos, MD,
PhD, FRCS(C),
FACS**

Associate Professor of
Surgery and Oncology,
McGill University
Hepato-Pancreato-Biliary
and Transplant Surgeon
McGill University
Health Center

SCIENTIFIC ADVISORY COMMITTEE

Members of the Scientific Advisory Committee volunteer their time and guide our organization on the strategic direction of our scientific programs and funding competitions.

We proudly welcomed Dr. Don Morris as President of the Committee and recognize his leadership, experience, and dedication.

In addition, five new members joined the committee, including four scientific experts: Dr. Doreen Ezeife, Dr. Carman Giacomantonio, Dr. Madhuri Koti, and Anita Koushik, PhD, as well as a patient advocate, Mr. Patrick Sullivan.

We would like to thank Marie-Élise Parent, PhD, and Lynne-Marie Postovit, PhD, for their contribution to the committee over the past few years.

President



**Dr. Don Morris,
MD, PhD**

Head, Department of Oncology, Cumming School of Medicine, University of Calgary
Head, Clinical Department of Oncology, Calgary Zone, Alberta Health Services
Professor of Oncology and Medicine, University of Calgary
Medical Director of the Tom Baker Cancer Centre
Medical Director of the Arthur J.E. Child Comprehensive Cancer Centre
Associate Senior Medical Director of Cancer Care Alberta, Alberta Health Services

Committee Members



Jacques Côté, PhD

Full Professor, Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval
Canada Research Chair in Chromatin Biology and Molecular Epigenetics
Fellow of the Royal Society of Canada (FRSC)



**Dr. Doreen Ezeife, MD,
MSc, FRCPC**

Medical Oncologist, Arthur J.E. Child Comprehensive Cancer Centre
Clinical Associate Professor, University of Calgary, Department of Oncology
Alberta Provincial Lung Tumour Lead



**Dr. Carman
Giacomantonio, MD,
MSc, FRCSC**

Professor of Surgery, Dalhousie University
Surgical Oncologist, QEII Health Sciences Centre
Gibran and Jamile Ramia Endowed Research Chair in Surgical Oncology
Chief Medical Officer for Sona Nanotech Inc.



Rama Khokha, PhD

Senior Scientist at the Princess Margaret Cancer Centre (PM), University Health Network
Full Professor in the Department of Medical Biophysics, cross appointed to the Department of Laboratory Medicine and Pathobiology, University of Toronto



**Dr. Madhuri Koti,
DVM, MVSc, PhD**

Associate Professor, Departments of Biomedical and Molecular Sciences, Obstetrics and Gynecology and Urology
Sinclair Cancer Research Institute
Queen's University



Anita Koushik, PhD

McGill University Chair in Community Cancer Care at St. Mary's
Director, McGill Division of Cancer Epidemiology
Professor, Gerald Bronfman Department of Oncology
Principal Scientist, St. Mary's Research Centre



**Christopher Ong,
PhD**

Associate Professor, Department of Urologic Sciences, University of British Columbia
Senior Research Scientist, Vancouver Prostate Centre



Patrick Sullivan

CRS Patient Advocate
Partner Chair of Canadian Commercial Litigation Lawyer, WT BCA LLP

MANAGEMENT TEAM

The CRS Management Team oversees a group of more than thirty dedicated professionals, brought together by a spirit of collaboration.

They are all driven by a shared goal: to maximize the impact of funds invested in research on all types of cancer.



Manon Pepin
President and Chief
Executive Officer



Tina Mignacca, CPA
Director, Finance
and Administration



Dajan O'Donnell, PhD
Director, Scientific Affairs
and Partnerships



Koudjo Oni, MBA
Director, Revenue
Development



Catherine Paquette
Director, Communications
and Marketing

STATE OF CANCER IN CANADA

Cancer remains the leading cause of death in Canada.

Every year, thousands of Canadians, and their loved ones, see their lives profoundly affected by the disease. These numbers reflect the magnitude of the challenge and remind us that cancer is a reality that can touch any one of us.



2 out of 5
Canadians will
develop cancer



1 in 4
patients will die of cancer

Understanding to Better Prevent

In recent years, scientists have sounded the alarm about a troubling rise in cancer among young people. Across the globe, experts are seeing more cases of breast, colon, ovarian, and testicular cancers, among individuals under the age of 50, a trend that can no longer be ignored. In less than 30 years, the number of diagnoses in this age group has surged by nearly 80%. The exact causes of this rise remain poorly understood, making research even more crucial. Understanding the underlying biological mechanisms, identifying contributing factors, and adapting prevention strategies are essential steps to reversing this trend.



Advancing Technology for Better Detection

Early detection has already proven its effectiveness. In the case of breast cancer, screening often allows the disease to be identified at an early stage, with five-year survival rates close to 100%. For other cancers, such as pancreatic and lung cancer, however, available tools remain limited and diagnoses often come too late. This is why investing in research is essential: it enables the development of promising technologies such as multi-cancer tests, liquid biopsies, and artificial intelligence, all aimed at detecting disease earlier, more precisely, and in a less invasive way.

Innovating for Better Treatment

Cancer treatments have evolved significantly thanks to research. Surgery, radiotherapy, and chemotherapy remain essential, but new approaches are transforming patient care. Immunotherapy helps the immune system target cancer cells while sparing healthy ones. Precision medicine tailors certain treatments to each patient's genetic profile, and targeted therapies act directly on tumors with fewer side effects. These advances, built on decades of research, offer more effective and personalized options. To ensure these breakthroughs continue and reach more people, ongoing support for research is vital.

RESEARCH

OUR IMPACT


Meeting the challenges of cancer requires resources that match the ambition to beat it. This is exactly what CRS has been delivering for over 80 years. By supporting groundbreaking research, CRS not only **accelerates discoveries** but also ensures that these advances translate into real, **life-changing impact**, helping us get closer every day to outsmarting cancer.

In 2024–2025, thanks to the generosity of its donors and partners, CRS invested over **\$17 million** in cancer research. This investment supports **316 projects**, each with the potential to transform the lives of people affected by cancer.


**4th Consecutive
Record Year for
Cancer Research**

13

Number of Funded Projects



Investments in Research (millions \$)



FUNDING ACROSS THE RESEARCH SPECTRUM

From the Laboratory to the Patient: Every Discovery Matters

At CRS, every discovery is viewed as a real opportunity to improve the lives of those affected by cancer. But this potential does not reveal itself overnight. It takes time to unravel the complexities of the disease, to turn ideas into solutions, and to bring them to patients. It's this journey, sometimes long but always essential, that CRS supports with unwavering determination, **because research is the key to outsmarting cancer.**

This journey is built on different types of research, each playing a vital role in advancing knowledge and developing new approaches to fight cancer.



Fundamental Research

Explores the biological foundations of cancer, analyzes its origins and mechanisms, and provides essential knowledge to identify new potential targets.



Translational Research

Converts fundamental discoveries into practical tools, such as new molecules or drugs, screening tests, or biomarkers, paving the way for their future application.



Clinical Research

Tests new approaches directly with patients to evaluate their effects, ensure safety, and confirm their potential to improve health outcomes.



EVALUATION COMMITTEES

Supporting Scientific Excellence

To ensure that every dollar invested supports the most promising research, CRS relies on the expertise of hundreds of researchers and physicians from across Canada who generously volunteer their time to review every application we receive.

This process allows the selection of the most impactful projects, those with the greatest potential to advance the fight against cancer.

Each project is evaluated to ensure:

scientific
quality

relevance

innovation

feasibility

potential
impact for
people affected
by cancer



10+
evaluation
committees



200+
researchers and
physician reviewers



700+
grant applications
received

ANNUAL PROGRAMS

Supporting the Work of Researchers

In every laboratory, students, postdoctoral fellows, and researchers join forces to push the boundaries of what we know about cancer. Through its **three annual grant programs**, CRS supports each of them, helping to foster the development of innovative solutions for all types of cancer.

A Strengthened Commitment

To better meet the growing needs of the research community, CRS has increased the amount of its Operating Grants and Next Generation of Scientists Awards by **\$5,000**, a revaluation that will be renewed next year.



Operating Grants

This program supports established researchers who are leading innovative projects with high potential for impact. With a grant of **\$130,000 over two years**, they have the resources needed to advance their discoveries and explore new promising avenues to overcome the disease.

This year, 100 new grants were awarded, bringing the total number of researchers currently being funded to 183.

[Learn more](#)

Next Generation of Scientists Awards – unique in Canada

This program helps attract and retain promising early-career scientists by providing **\$180,000 over three years** giving them the resources to establish their laboratories and launch their cancer research projects in Canada.

This year, 8 new grants were awarded, bringing the total number of researchers currently being funded to 18.

[Learn more](#)

Doctoral Research Awards

Doctoral students are at the heart of scientific innovation. By providing **\$70,000 over two years**, CRS enables them to fully dedicate themselves to their research and develop their expertise in the field of cancer.

This year, 40 new grants were awarded, bringing the total number of students currently being funded to 61.

[Learn more](#)

TARGETED PROGRAMS

Supporting High-Impact Initiatives

Beyond its annual programs, CRS occasionally launches initiatives to address specific scientific needs. These **targeted programs**, made possible through partnerships or major donations, support projects in defined areas, such as specific cancer types or emerging scientific challenges. They all share a common goal: advancing research to outsmart the disease.

Bringing Biology to Cancer Prevention Team Grants



In partnership with the Canadian Institutes of Health Research – Institute of Cancer Research, CRS is committed to supporting two interdisciplinary research teams, with a total investment of \$4 million. These projects aim to deepen the understanding of the biological and mechanistic origins of cancer, while also exploring lifestyle, environmental, and social factors. By taking this integrated approach, researchers seek to uncover new avenues to prevent cancer and protect the health of communities across Canada.

Prostate Cancer Research Grants



Prostate cancer is the most commonly diagnosed cancer among men in Canada. To address this major health challenge, CRS, in collaboration with PROCURE, launched a targeted program with a total investment of \$2 million. Through this initiative, four translational research projects will be funded to improve early detection and develop more effective treatments, ultimately helping to improve outcomes and quality of life for those affected.

Blood Cancer Research Grants



For several years, CRS and the Leukemia & Lymphoma Society of Canada have joined forces in a strategic partnership to accelerate research on blood cancers. Over the past 2 years, this collaboration has supported a total of 25 projects, exploring new therapeutic approaches and deepening our understanding of complex forms of leukemia and lymphoma. It reflects the shared commitment of both organizations to research and innovation in the fight against all types of blood cancer.

CLINICAL TRIALS

Supporting Research That Serves Patients

Scientific discoveries reach their full meaning when they are brought closer to the realities experienced by patients. By supporting researcher-led clinical trials, CRS invests in concrete, rigorous, and high-impact projects. These trials make it possible to test new approaches directly with people affected by cancer, advancing research where it can truly change lives.

Currently, CRS supports **5 clinical trials**, each addressing different types of cancer, including pediatric, blood, brain, and gynecological cancers. Among them, OPTIMISE exemplifies CRS's mission: turning research into tangible progress for patients.

Personalized Treatments for Young Patients

The OPTIMISE clinical trial aims to provide more tailored treatments for children, adolescents, and young adults with hard-to-treat cancers. Using a precision medicine approach, each tumor is genetically analyzed to guide patients toward the therapy most likely to help them. Unlike traditional trials, OPTIMISE allows multiple options to be tested in parallel. The first treatment option evaluates a combination of chemotherapy and a drug that specifically targets cancer cell growth. This innovative project is paving the way for more precise care, better adapted to the needs of young patients.





PROMISING RESEARCH PROJECTS

Research That Brings Hope

Behind every grant are researchers who dedicate their time, energy, and expertise to advancing science for the benefit of people affected by cancer. Their commitment is deep, their work demanding, and their motivation driven by the desire to understand, innovate, and contribute to real-world solutions.

Here are three examples of promising research supported by CRS, pushing the boundaries of knowledge to better prevent the disease, improve detection, and enhance treatment effectiveness.

Prevent



Marie-Claude Rousseau, PhD
*National Institute of Scientific Research
(Quebec)*

A Vaccine to Prevent Cancer?

The *Bacillus Calmette-Guérin* (BCG) vaccine, used against tuberculosis, may also offer protection against certain cancers. Researcher Marie-Claude Rousseau, at the National Institute of Scientific Research, is testing this hypothesis using a unique cohort of 400,000 people. By comparing the health trajectories of vaccinated and unvaccinated individuals, her team aims to determine whether BCG has a protective effect and can reduce cancer risk in the long term. These findings could pave the way for new, effective, and accessible prevention strategies.

Detect



Dr. Rodney Ouellette, MD, PhD
*Atlantic Cancer Research Institute
(New Brunswick)*

Monitoring Cancer Risk Differently

Women carrying genetic mutations such as BRCA1/2 face a high risk of developing breast cancer, but current monitoring methods remain limited and sometimes invasive. Researcher Rodney Ouellette, at the Atlantic Cancer Research Institute, is studying tiny particles in the blood that carry revealing genetic information potentially indicating the presence of cancer. His goal is to develop a blood test to provide a more specific, less invasive, and more accessible detection method.

Treat



Sachin Katyal, PhD
University of Manitoba (Manitoba)

How to Counter Treatment Resistance?










Glioblastoma multiforme is one of the most aggressive brain cancers. Despite surgery, radiation, and chemotherapy, it often recurs and resists treatment. Researcher Sachin Katyal at the University of Manitoba is exploring a new therapeutic approach by targeting a protein called XRCC1, which may explain this resistance. His team is evaluating existing drugs as well as a new compound developed in the lab to block this molecule and make tumors sensitive to chemotherapy again. This promising advance could help improve treatment for this devastating cancer.

CANCER RESEARCH FUNDING

Annual Programs

	Operating Grants	183
	Next Generation of Scientists Awards	18
	Doctoral Research Awards	61
	Scholarships for undergraduate students	2

Additional Programs

	Lung Cancers	6		Prevention	2
	Ovarian Cancers	3		Upcycle: Drug Repurposing	2
	Blood Cancers	25		International Partnerships	4
	Brain Cancers	2		Research Training Awards	3
	Clinical Trials	5			

Total Projects Funded:

316

Total Investment:

\$17 million

(includes administrative costs)

SIGNATURE EVENTS

The CRS' three signature events sparked a wave of generosity over the past year. Thanks to the dedication of their organizing committees, these events brought together a vibrant community of donors and partners united by a common cause: funding innovative research projects to outsmart cancer.



Over
\$214,000
net

22

Cyclo-Golf Classic 2024

The 30th edition of the Montreal Classic and the 7th Cyclo-Walk Sherbrooke brought together passionate athletes and raised a record-breaking amount for cancer research. What an outstanding achievement!

[Read the article](#)

Scotiabank.

BMO  Insurance



Over
\$380,600
net

Accords Célestes 2024

The 7th edition of the Accords Célestes evening, presented by the MTY Group, was filled with culinary and musical discoveries. Once again, this unforgettable night left a lasting impression on our guests.



[Read the article](#)



Over
\$900,000
net

Urban BBQ 2025

More than 1,000 guests attended the 11th edition of the Urban BBQ. A very special thank you to our presenting partner, RBC Royal Bank (Quebec), for their invaluable support. This event has truly become a must-attend for cancer research!



[Read the article](#)





In 2025, the Challenge Against Cancer program raised over **\$440,000 net** for cancer research. Each of our participants organized a fundraiser and traveled to dream destinations with the goal of pushing themselves both physically and mentally for the cause.

In Corsica, New York City, Colombia, Vietnam, Greece, and Portugal, they moved cancer research forward, one step at a time.

CRS congratulates all participants on their outstanding determination and commitment.

[Learn more](#)



Supporting Breast Cancer Research

In 2025, a new initiative was launched within the program. Led by our ambassador, Kim Joubert, this new challenge was designed specifically to support breast cancer research. In October 2026, the first group will head to Guatemala with one shared goal: to push their limits in support of breast cancer research.

[Learn more](#)



André Robitaille, CRS' Spokesperson

Known for his many talents on stage and on television, André Robitaille has been a longtime ally of CRS and a dedicated ambassador for the Challenge Against Cancer program.

After taking on two challenges in 2023 and 2024, during which he highlighted the touching stories of several participants, he is now embarking on a new adventure: Morocco in 2026.

Cambodge, 2024 (Video in French only)



Create Your Own Challenge Against Cancer

In 2025, five passionate individuals organized their own adventure as part of the Challenge Against Cancer program and climbed Mount Kilimanjaro, Africa's highest peak at 5,895 meters. They raised an impressive amount of over **\$111,800 net** for cancer research.

Just like these participants, anyone can create their own challenge in support of CRS through our Challenge Against Cancer program. Imagine a challenge that reflects who you are, shared with your loved ones: choose your dream destination, map out your own route, and set a difficulty level that will truly push your limits.

[Learn more](#)

FINANCIAL INFORMATION

\$37.7 MILLION
RESEARCH PROGRAM
COMMITMENTS SPREAD OVER
SEVERAL YEARS UP TO 2030

SUMMARY OF REVENUES AND EXPENSES

From September 1st, 2024 to August 31st, 2025

(in thousands of dollars)	2025 Total	2024 Total
REVENUES		
Annual campaigns	24,323	24,789
Major donations and planned giving	3,861	2,730
Benefit events and others	4,764	3,477
Partnerships – Research contributions	1,633	2,367
Investment income, realized	4,388	3,320
Investment income, unrealized	1,823	4,048
	40,792	40,731
EXPENDITURES		
Annual campaigns	12,210	13,755
Major donations and planned giving	268	228
Benefit events and others	1,882	1,798
Administration	1,756	1,566
Depreciation of fixed assets	55	54
	16,171	17,401
SURPLUS AVAILABLE FOR RESEARCH	24,621	23,330
GRANTS AND FELLOWSHIPS (including related expenses)	16,976	15,332
EXCESS OF REVENUES OVER EXPENDITURES	7,645	7,998

SUMMARY OF THE STATEMENT OF FINANCIAL CONDITION

On August 31st, 2025

(in thousands of dollars)		2025 Total	2024 Total
ASSETS			
Cash		6,970	2,196
Accounts receivable		63	104
Prepaid expenses		147	227
Other current assets		77	83
Short-term investments		0	7,000
		7,257	9,610
Investments		68,051	59,779
Fixed assets		340	214
		75,648	69,603
LIABILITIES			
Accounts payable and accrued liabilities		834	2,071
Deferred contributions – Short term		580	926
		1,414	2,997
Lease inducement		42	58
		1,456	3,055
FUND BALANCES			
Allocated funds		7,057	6,460
General funds		67,135	60,088
		74,192	66,548
		75,648	69,603



TRANSFORMING THE **FUTURE**, ONE DISCOVERY AT A TIME

28

For over 80 years, CRS has pursued its mission with unwavering determination, thanks to the generosity of thousands of donors, and the outstanding commitment of its partners. Together, we are helping advance science to better prevent, detect, and treat the disease.

This report highlights the scientific breakthroughs made possible through our impactful and hopeful projects, born from numerous and diverse strategic initiatives carried out over the past year.

Let's continue pushing the boundaries of science. Let's take part in a future where every action and every donation help accelerate discoveries and amplify the impact of cancer research.

Montreal

625, President-Kennedy Avenue
Suite 402
Montreal (Quebec)
H3A 3S5

Ottawa

P.O. 4613, Station E
Ottawa (Ontario)
K1S 1P7

Phone: 514-861-9227
Toll-free number: 1-866-343-2262
Email: info@src-crs.ca

CANCERRESEARCHSOCIETY.CA

